IGF-1和IGFBP-3在生长激素治疗中的安全性和有效性的研究

IGF-1 and IGFBP-3 in the safety and efficacy of growth hormone treatment

基因重组人生长激素（recombinant human growth hormone，rhGH）已广泛应用于儿科临床治疗生长激素缺乏症，并已取得较满意的疗效。生长激素（growthhormone，GH）通过刺激肝脏细胞产生胰岛素样生长因子（insulin-like growth actor，IGF-1）来介导GH的促生长作用。血浆中大部分IGF-1与胰岛素样生长因子结合蛋白3结合，IGF-1具有促进细胞有丝分裂抑制细胞凋亡的作用，近年来发现IGF-1与肿瘤的发生发展有一定相关性，因而引发了对rhGH治疗的安全性和有效性的关注。

Recombinant human growth hormone （rhGH） has been widely used in clinical treatment of growth hormone deficiency（ GHD）, and has achieved satisfactory effect. Growth hormone （GH） can stimulate liver cells to produce insulin-like growth actor（ IGF-1 ） which mediated GH growth promoting effect. The majority of IGF-1 combine with insulin like growth factor binding protein 3. IGF-1 promotes cell mitotic and inhibit cell apoptosis,in recent years, some scholars have reported that there is a certain relationship between IGF-1 and tumor occurrence and development, and thus leading to the attention to the efficacy and safety of rhGH treatment.